Physician profile
Robert Paul
NPI 1386626109
$8,753.32
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,416 · 2020: $2,144 · 2021: $193.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $708.98 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $696.10 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $641.63 | 2019-2020 | |
| Novo Nordisk INC | $603.32 | 2019-2020 | |
| Lantheus Medical Imaging, INC. | $577.92 | 2019-2020 | |
| Amgen INC. | $442.92 | 2019-2020 | |
| Inari Medical, INC. | $424.70 | 2020-2021 | |
| Pfizer INC. | $423.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $358.84 | 2019-2020 | |
| Tactile Systems Technology INC | $260.30 | 2019-2021 | |
| Smith+Nephew, INC. | $256.66 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $228.18 | 2019 | |
| Sanofi-Aventis U.S. LLC | $216.17 | 2019 | |
| Glaxosmithkline, LLC. | $213.33 | 2019 | |
| Amarin Pharma, INC. | $197.81 | 2020-2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicure Pharma INC. | $181.68 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $169.92 | 2019 | |
| Merck Sharp & Dohme LLC | $142.10 | 2019-2020 | |
| Chiesi USA, INC. | $137.60 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $129.78 | 2019 | |
| Lundbeck LLC | $126.13 | 2019 | |
| Portola Pharmaceuticals, LLC | $125.00 | 2019 | |
| Celgene Corporation | $125.00 | 2019 | |
| Rigel Pharmaceuticals, INC. | $125.00 | 2019 | |
| Osiris Therapeutics INC. | $121.68 | 2019 | |
| Abbott Laboratories | $117.70 | 2019 | |
| Boston Scientific Corporation | $115.65 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.54 | 2019 | |
| Biocompatibles, INC. | $110.49 | 2019 | |
| Allergan, INC. | $100.00 | 2019 | |
| Astellas Pharma US INC | $87.72 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.22 | 2019 | |
| Novocure INC. | $79.45 | 2019 | |
| Organogenesis INC. | $78.17 | 2019 | |
| Alnylam Pharmaceuticals INC. | $64.55 | 2019 | |
| Zimmer Biomet Holdings, INC. | $61.35 | 2019 | |
| Jazz Pharmaceuticals INC. | $51.69 | 2019 | |
| Lilly USA, LLC | $44.44 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $6.77 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.